Modification of the fatty acid composition of the erythrocyte membrane in patients with chronic respiratory diseases

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Novgorodtseva, Tatyana P ^a   Denisenko, Yulia K ^a   Zhukova, Natalia V ^b,c   Antonyuk, Marina V ^a   Knyshova, Vera V ^a   Gvozdenko, Tatyana A ^a  

^a Russian Academy of Medical Sciences   (Russian Federation)

^b INSTITUTE OF MARINE BIOLOGY   (Russian Federation)

^c FAR EASTERN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

Chronic respiratory diseases; Fatty acids; Red blood cell membrane

Indexed keywords

ARACHIDONIC ACID; DOCOSAPENTAENOIC ACID; FIBROBLAST GROWTH FACTOR 2; ICOSAPENTAENOIC ACID; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BRONCHOSPASM; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FATTY ACID ANALYSIS; FEMALE; HUMAN; IMMUNE STATUS; LIPID COMPOSITION; MALE; NEUTROPHIL; PHAGOCYTOSIS; PROTEIN BLOOD LEVEL;

ADULT; BRONCHITIS, CHRONIC; EICOSAPENTAENOIC ACID; ERYTHROCYTE MEMBRANE; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-8; MALE; MIDDLE AGED; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84880908431     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-117     Document Type: Article

References (34)

1. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 [Accessed November 10, 2012]. Available from: http://www.goldcopd.org
2. Prioritised research agenda for prevention and control of chronic respiratory diseases. Bousquet J, Kiley J, Bateman ED, Viegi G, Cruz AA, Khaltaev N, Aït Khaled N, Baena-Cagnani CE, Barreto ML, Billo N, Canonica GW, Carlsen KH, Chavannes N, Chuchalin A, Drazen J, Fabbri LM, Gerbase MW, Humbert M, Joos G, Masjedi MR, Makino S, Rabe K, To T, Zhi L, Eur Respir J 2010 36 5 995 1001 10.1183/09031936.00012610 20223919
3. Chronic obstructive pulmonary disease. Singh S, Curr Anaest Crit Care 2003 14 74 80 10.1016/S0953-7112(03)00032-2 (Pubitemid 36987021)
4. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD, Thorax 2009 64 894 900 10.1136/thx.2008.110619 19581277
5. Epidemiology of chronic bronchitis and acute infective exacerbations of chronic bronchitis. Kim N, Leeper KV Jr, Semin Respir Crit Care Med 2000 21 2 73 78 10.1055/s-2000-9845 16088720 (Pubitemid 30463939)
6. The natural history of chronic airflow obstruction. Fletcher C, Peto R, BMJ 1977 1 1645 1648 10.1136/bmj.1.6077.1645 871704 (Pubitemid 8124466)
7. Association between chronic mucus hypersecretion with FEV1 decline and COPD morbidity. Vestbo J, Prescott E, Lange P, Am J Respir Crit Care Med 1996 153 1530 1535 10.1164/ajrccm.153.5.8630597 8630597 (Pubitemid 26141336)
8. Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. Sutherland ER, Martin RJ, J Allergy Clin Immunol 2003 112 819 27 10.1016/S0091-6749(03)02011-6 14610463 (Pubitemid 37412048)
9. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, Calverley P, Coxson H, Crim C, Edwards LD, Lomas DA, Duvoix A, MacNee W, Rennard S, Silverman E, Vestbo J, Wouters E, Agustí A, Am J Respir Crit Care Med 2012 185 10 1065 1072 10.1164/rccm.201110-1792OC 22427534
10. Chemokines and their receptors in chronic pulmonary disease. Lukacs NW, Hogaboam CM, Kunkel SL, Curr. Drug Targets Inflamm 2005 4 313 317 10.2174/1568010054022088 (Pubitemid 40873117)
11. Endogenous lipid mediators in the resolution of airway inflammation. Haworth O, Levy BD, Eur Respir J 2007 30 980 992 10.1183/09031936.00005807 17978156 (Pubitemid 351194804)
12. The cytokine network in asthma and chronic obstructive pulmonary disease. Barnes PJ, J Clin Invest 2008 118 11 3546 3556 10.1172/JCI36130 18982161
13. Leukotiene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma. Kostikas K, Gaga M, Papatheodorou G, Karamanis T, Orphanidou D, Loukides S, Chest 2005 127 155 39
14. Expression of epidermal growth factors and their receptors in the bronchial epithelium of subjects with chronic obstructive pulmonary disease. De Boer WI, Hau CM, Van Schadewijk A, Stolk J, Van Krieken JH, Hiemstra PS, Am J Clin Pathol 2006 125 184 192 16393673 (Pubitemid 43167158)
15. Interleukin-8 receptor antagonists in pulmonary diseases. Hay DWP, Sarau HM, Curr Opin Pharmacol 2001 1 242 247 10.1016/S1471-4892(01)00043-1 11712746 (Pubitemid 33585969)
16. Measurement of tumour necrosis factor-alpha, leukotriene B4, and interleukin 8 in exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease. Ko FW, Leung TF, Wong GW, Ngai J, To KW, Ng S, Hui DS, Int J Chron Obstruct Pulmon Dis 2009 4 79 86 19436689
17. Leukotrienes: underappreciated mediators of innate immune responses. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ, J Immunol 2005 174 589 594 15634873 (Pubitemid 40103563)
18. Role of polyunsaturated fatty acids in lung disease. Schwartz J, Am J Clin Nutr 2000 71 1 Suppl 393S 396S 10618003 (Pubitemid 30046148)
19. Association of fatty acids in serum phospholipids with lung function and bronchial hyperresponsiveness in adults. Kompauer I, Demmelmair H, Koletzko B, Bolte G, Linseisen J, Heinrich J, Eur J Epidemiol 2008 23 3 175 190 10.1007/s10654-007-9218-y 18204906
20. Biophysical properties of lipids and dynamic membranes. Janmey PA, Kinnunen PK, Trends Cell Biol 2006 16 10 538 546 10.1016/j.tcb.2006.08.009 16962778 (Pubitemid 44468385)
21. Mechanisms of initiation of membrane fusion: role of lipids. Kinnunen PK, Holopainen JM, Biosci Rep 2000 20 6 465 482 10.1023/A:1010402819509 11426689 (Pubitemid 32523206)
22. Eicosanoids and the endogenous control of acute inflammatory resolution. Gilroy DW, Int J Biochem Cell Biol 2010 42 4 524 528 10.1016/j.biocel.2009.12. 013 20026423
23. Lipid rafts and B-cell activation. Pierce SK, Nat Rev Immunol 2002 2 2 96 105 10.1038/nri726 11910900 (Pubitemid 37323233)
24. Comparison of changes in erythrocyte and platelet phospholipid and fatty acid composition and protein oxidation in chronic obstructive pulmonary disease and asthma. De Castro J, Hernández-Hernández A, Rodríguez MC, Sardina JL, Llanillo M, Sánchez-Yagüe J, Platelets 2007 18 1 43 51 10.1080/09537100600800776 17365853
25. Lipids of erythrocyte membranes of COPD patients: a quantitative and qualitative study. Gangopadhyay S, Vijayan VK, Bansal SK, COPD 2012 9 4 322 331 22497562
26. Comprehensive assessment of the function of phagocytes in inflammatory diseases: methodological recommendations. Mayansky DN, Shcherbakov VI, Makarova OP, Novosibirsk 1988 24
27. Lipid composition of erythrocytes at cardiovascular and hepatobiliary diseases. Zhukova NV, Novgorodtseva TP, Lipids: Categories, Biological functions and metabolism, nutrition and health NY: Nova Science Publishers, Inc, Gilmore PL, 2010 1 45
28. A rapid method of total lipid extraction and purification. Bligh EG, Dyer WJ, Can J Biochem Physiol 1959 37 911 917 10.1139/o59-099 13671378
29. Adaptation of a macroscale method to the microscale for fatty acid methyl transesterification of biological lipid extract. Carreau JP, Duback JP, J Chromatogr 1978 151 3 384 390 10.1016/S0021-9673(00)88356-9 (Pubitemid 8343999)
30. Equivalent chain-lengths of methyl ester derivatives of fatty acids on gas-chromatography-a reappraisal. Christie WW, J Chromatogr 1978 447 2 305 314
31. Clinical and experimental pathophysiology of the lungs. Motavkin PA, Gelzer BI, Nauka 1998 366
32. Composition of fatty acids in plasma and erythrocytes and eicosanoids level in patients with metabolic syndrome. Novgorodtseva TP, Karaman YK, Zhukova NV, Lobanova EG, Antonyuk MV, Kantur TA, Lipids Health Dis 2011 10 82 doi:10.1186/1476-511X-10-82 http://www.lipidworld.com/content/10/1/82 10.1186/1476-511X-10-82 21595891
33. Lipoxygenase-Derived Arachidonic Acid Metabolites in Chronic Obstructive Pulmonary Disease. Balode L, Strazda G, Jurka N, Kopeika U, Kislina A, Bukovskis M, Beinare M, Gardjušina V, Taivāns I, Medicina (Kaunas) 2012 48 6 292 8
34. Arachidonic acid as a bioactive molecule. Brash AR, J Clin Invest 2001 107 1339 1345 10.1172/JCI13210 11390413 (Pubitemid 32522025)